References
1. Kattamis A, Kwiatkowski JL, Aydinok Y. Thalassaemia. Lancet
2022;399(10343):2310-2324.
2. Goh LPW, Chong ETJ, Lee PC. Prevalence of alpha-thalassemia in
Southeast Asia (2010-2020): A meta-analysis involving 83,674 subjects.
Int J Environ Res Public Health 2020;17(20).
3. Piel FB, Weatherall DJ. The alpha-thalassemias. N Engl J Med
2014;371(20):1908-1916.
4. Singer ST, Kim HY, Olivieri NF, Kwiatkowski JL, Coates TD, Carson S,
et al. Hemoglobin h-constant spring in north america: An
alpha-thalassemia with frequent complications. Am J Hematol
2009;84(11):759-761.
5. Wong P, Fuller PJ, Gillespie MT, Milat F. Bone disease in
thalassemia: A molecular and clinical overview. Endocr Rev
2016;37(4):320-346.
6. Dede AD, Trovas G, Chronopoulos E, Triantafyllopoulos IK, Dontas I,
Papaioannou N, et al. Thalassemia-associated osteoporosis: A systematic
review on treatment and brief overview of the disease. Osteoporos Int
2016;27(12):3409-3425.
7. Farr JN, Melton LJ, 3rd, Achenbach SJ, Atkinson EJ, Khosla S, Amin S.
Fracture incidence and characteristics in young adults aged 18 to 49
years: A population-based study. J Bone Miner Res 2017;32(12):2347-2354.
8. Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N,
Kwiatkowski J, et al. Prevalence of fractures among the thalassemia
syndromes in north america. Bone 2006;38(4):571-575.
9. Charoenngam N, Rittiphairoj T, Ponvilawan B. Fracture prevalence in
thalassemia: A systematic review and meta-analysis. Arch Osteoporos
2021;16(1):171.
10. Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JC,
et al. Thalassemia bone disease: A 19-year longitudinal analysis. J Bone
Miner Res 2014;29(11):2468-2473.
11. Piriyakhuntorn P, Tantiworawit A, Phimphilai M, Srichairatanakool S,
Teeyasoontranon W, Rattanathammethee T, et al. Prevalence and risk
factors of low bone mineral density and fractures of young thalassemia
patients. Blood 2018;132(Suppl 1):3636-3636.
12. Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri
N, et al. Bone disease in thalassemia: A frequent and still unresolved
problem. J Bone Miner Res 2009;24(3):543-557.
13. Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ.
Low bone mineral density in adolescents with beta-thalassemia. Ann N Y
Acad Sci 2005;1054(1):462-466.
14. McCormack SE, Cousminer DL, Chesi A, Mitchell JA, Roy SM, Kalkwarf
HJ, et al. Association between linear growth and bone accrual in a
diverse cohort of children and adolescents. JAMA Pediatr
2017;171(9):e171769.
15. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and dickkopf-1 as
therapeutic targets in bone diseases. Endocr Rev 2012;33(5):747-783.
16. Sapunarova K, Goranova-Marinova V, Georgiev P, Deneva T, Tsvetkova
S, Grudeva-Popova Z. Associations of serum sclerostin with bone mineral
density, markers of bone metabolism and thalassaemia characteristics in
adult patients with transfusion-dependent beta-thalassaemia. Ann Med
2020;52(3-4):94-108.
17. Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis
AD, Komninaka V, et al. High circulating sclerostin is present in
patients with thalassemia-associated osteoporosis and correlates with
bone mineral density. Horm Metab Res 2012;44(12):909-913.
18. Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G,
Bilalis A, et al. Serum dickkopf-1 is increased and correlates with
reduced bone mineral density in patients with thalassemia-induced
osteoporosis. Reduction post-zoledronic acid administration.
Haematologica 2009;94(5):725-728.
19. Ahmed SF, Fouda N, Abbas AA. Serum dickkopf-1 level in
postmenopausal females: Correlation with bone mineral density and serum
biochemical markers. J Osteoporos 2013;2013:460210.
20. Huang Y, Eapen E, Steele S, Grey V. Establishment of reference
intervals for bone markers in children and adolescents. Clin Biochem
2011;44(10-11):771-778.
21. Choi JS, Park I, Lee SJ, Ju HJ, Lee H, Kim J. Serum procollagen
type-I N-terminal propeptide and osteocalcin levels in Korean children
and adolescents. Yonsei Med J 2019;60(12):1174-1180.
22. Nakavachara P, Pooliam J, Weerakulwattana L, Kiattisakthavee P,
Chaichanwattanakul K, Manorompatarasarn R, et al. A normal reference of
bone mineral density (bmd) measured by dual energy x-ray absorptiometry
in healthy Thai children and adolescents aged 5-18 years: A new
reference for Southeast Asian populations. PLoS One 2014;9(5):e97218.
23. Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd
JA, et al. Revised reference curves for bone mineral content and areal
bone mineral density according to age and sex for black and non-black
children: Results of the Bone Mineral Density in Childhood study. J Clin
Endocrinol Metab 2011;96(10):3160-3169.
24. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse
LR, et al. Executive summary of the 2019 ISCD position development
conference on monitoring treatment, DXA cross-calibration and least
significant change, spinal cord injury, peri-prosthetic and orthopedic
bone health, transgender medicine, and pediatrics. J Clin Densitom
2019;22(4):453-471.
25. Pirinççioğlu AG, Akpolat V, Köksal O, Haspolat K, Söker M. Bone
mineral density in children with beta-thalassemia major in Diyarbakir.
Bone 2011;49(4):819-823.
26. Kothimira VK, Kumar A, Richhele LR, Sood N, Gulati A. An evaluation
of bone health parameters in regularly transfused beta-thalassemia major
patients. J Pediatr Hematol Oncol 2020;42(6):381-385.
27. Nakavachara P, Petchkul J, Jeerawongpanich K, Kiattisakthavee P,
Manpayak T, Netsakulnee P, et al. Prevalence of low bone mass among
adolescents with nontransfusion-dependent hemoglobin E/beta-thalassemia
and its relationship with anemia severity. Pediatr Blood Cancer
2018;65(1).
28. Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L.
Longitudinal monitoring of bone mineral density in thalassemic patients.
Genetic structure and osteoporosis. Acta Paediatr 1997;86(4):342-346.
29. Murphy WG. The sex difference in haemoglobin levels in adults -
Mechanisms, causes, and consequences. Blood Rev 2014;28(2):41-47.
30. Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou
S, et al. Gender differences in the prevalence and severity of bone
disease in thalassaemia. Pediatr Endocrinol Rev 2008;6(Suppl 1:)116-122.
31. Tari E, Vörhendi N, Kiss S, Teutsch B, Váradi A, Sisák K, et al.
Anaemia is associated with an increased risk of fractures, a systematic
review, and meta-analysis. Gerontology 2023;69(1):1-13.
32. Harrison-Findik DD. Gender-related variations in iron metabolism and
liver diseases. World J Hepatol 2010;2(8):302-310.
33. Aikaterini N, Chrisavgi T, Pavlos F, Nicoletta B, Lucia Carmela C,
Cristina Z, et al. Sex-specific transcriptional profiles identified in
β-thalassemia patients. Haematologica 2020;106(4):1207-1211.
34. Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin
signalling: Function, biological mechanisms, and therapeutic
opportunities. Signal Transduc Target Ther 2022;7(1):3.
35. Badiee Z, Sepasizang abadi M, Keshavarzi A, Keramati MR, Ayatollahi
H, Sadeghian MH, et al. Serum dickkopf-1 and correlation with bone
mineral density in patients with beta thalassemia major in North-Eastern
of Iran. ssu-ijml 2018;5(3):188-194.
36. Chiarito M, Piacente L, Chaoul N, Pontrelli P, D’Amato G, Grandone
A, et al. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone
fragility associated with Turner syndrome. J Endocrinol Invest
2022;45(6):1255-1263.
37. Xu Y, Gao C, He J, Gu W, Yi C, Chen B, et al. Sclerostin and its
associations with bone metabolism markers and sex hormones in healthy
community-dwelling elderly individuals and adolescents. Front Cell Dev
Biol 2020;8:57.
38. Mödder UIL, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ,
et al. Regulation of circulating sclerostin levels by sex steroids in
women and in men. J Bone Miner Res 2011;26(1):27-34.
39. Khalil R, Antonio L, Laurent MR, David K, Kim NR, Evenepoel P, et
al. Early effects of androgen deprivation on bone and mineral
homeostasis in adult men: A prospective cohort study. Eur J Endocrinol
2020;183(2):181-189.